QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:NBIX

Neurocrine Biosciences Competitors

$109.43
-0.08 (-0.07 %)
(As of 03/1/2021 05:14 PM ET)
Add
Compare
Today's Range
$108.43
Now: $109.43
$111.05
50-Day Range
$106.02
MA: $112.55
$119.40
52-Week Range
$72.14
Now: $109.43
$136.26
Volume401,413 shs
Average Volume897,288 shs
Market Capitalization$10.28 billion
P/E Ratio117.67
Dividend YieldN/A
Beta1.01

Competitors

Neurocrine Biosciences (NASDAQ:NBIX) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying NBIX stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Neurocrine Biosciences, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Amgen and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.61$7.84 billion$14.8215.32
Neurocrine Biosciences$788.10 million13.04$37.01 million$0.39280.59

Amgen has higher revenue and earnings than Neurocrine Biosciences. Amgen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Amgen and Neurocrine Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen0111402.56
Neurocrine Biosciences081102.58

Amgen presently has a consensus price target of $256.4091, indicating a potential upside of 12.94%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 18.09%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Amgen.

Profitability

This table compares Amgen and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Neurocrine Biosciences8.96%18.18%9.50%

Gilead Sciences (NASDAQ:GILD) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Gilead Sciences and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.49$5.39 billion$6.1410.17
Neurocrine Biosciences$788.10 million13.04$37.01 million$0.39280.59

Gilead Sciences has higher revenue and earnings than Neurocrine Biosciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Gilead Sciences and Neurocrine Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences1121202.44
Neurocrine Biosciences081102.58

Gilead Sciences presently has a consensus price target of $96.0370, indicating a potential upside of 53.76%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 18.09%. Given Gilead Sciences' higher probable upside, equities analysts plainly believe Gilead Sciences is more favorable than Neurocrine Biosciences.

Profitability

This table compares Gilead Sciences and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Neurocrine Biosciences8.96%18.18%9.50%

Vertex Pharmaceuticals (NASDAQ:VRTX) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.14$1.18 billion$4.2949.04
Neurocrine Biosciences$788.10 million13.04$37.01 million$0.39280.59

Vertex Pharmaceuticals has higher revenue and earnings than Neurocrine Biosciences. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Vertex Pharmaceuticals and Neurocrine Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042312.89
Neurocrine Biosciences081102.58

Vertex Pharmaceuticals presently has a consensus price target of $291.8462, indicating a potential upside of 38.72%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 18.09%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Vertex Pharmaceuticals is more favorable than Neurocrine Biosciences.

Profitability

This table compares Vertex Pharmaceuticals and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Neurocrine Biosciences8.96%18.18%9.50%

Summary

Vertex Pharmaceuticals beats Neurocrine Biosciences on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Regeneron Pharmaceuticals and Neurocrine Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals061512.77
Neurocrine Biosciences081102.58

Regeneron Pharmaceuticals presently has a consensus price target of $625.8077, indicating a potential upside of 35.15%. Neurocrine Biosciences has a consensus price target of $129.2222, indicating a potential upside of 18.09%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Regeneron Pharmaceuticals is more favorable than Neurocrine Biosciences.

Profitability

This table compares Regeneron Pharmaceuticals and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Neurocrine Biosciences8.96%18.18%9.50%

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.31$2.12 billion$21.4721.57
Neurocrine Biosciences$788.10 million13.04$37.01 million$0.39280.59

Regeneron Pharmaceuticals has higher revenue and earnings than Neurocrine Biosciences. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Neurocrine Biosciences on 11 of the 15 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neurocrine Biosciences and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences081102.58
Biogen5151202.22

Neurocrine Biosciences currently has a consensus target price of $129.2222, indicating a potential upside of 18.09%. Biogen has a consensus target price of $304.4667, indicating a potential upside of 11.43%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Biogen.

Profitability

This table compares Neurocrine Biosciences and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
Biogen35.63%51.00%23.54%

Risk and Volatility

Neurocrine Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Insider & Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neurocrine Biosciences and Biogen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million13.04$37.01 million$0.39280.59
Biogen$14.38 billion2.90$5.89 billion$33.578.14

Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Neurocrine Biosciences and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences081102.58
Alexion Pharmaceuticals017712.36

Neurocrine Biosciences currently has a consensus target price of $129.2222, indicating a potential upside of 18.09%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 0.76%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Neurocrine Biosciences and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
Alexion Pharmaceuticals16.32%23.16%14.76%

Risk and Volatility

Neurocrine Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

95.3% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Neurocrine Biosciences and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million13.04$37.01 million$0.39280.59
Alexion Pharmaceuticals$4.99 billion6.69$2.40 billion$9.7415.60

Alexion Pharmaceuticals has higher revenue and earnings than Neurocrine Biosciences. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Neurocrine Biosciences on 8 of the 15 factors compared between the two stocks.


Neurocrine Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$227.04-0.9%$131.13 billion$23.36 billion18.31Analyst Report
Gilead Sciences logo
GILD
Gilead Sciences
2.8$62.46-1.7%$78.30 billion$22.45 billion64.39
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$210.38-1.0%$54.69 billion$4.16 billion26.56Analyst Upgrade
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$463.05-2.7%$48.27 billion$7.86 billion16.92Analyst Report
Biogen logo
BIIB
Biogen
1.9$273.24-0.1%$41.62 billion$14.38 billion9.04
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$151.97-0.5%$33.41 billion$4.99 billion35.51Increase in Short Interest
Seagen logo
SGEN
Seagen
1.5$152.55-0.9%$27.38 billion$916.71 million60.06Decrease in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.6$140.21-2.9%$23.71 billion$876.29 million-63.44Gap Down
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$148.75-0.4%$17.33 billion$219.75 million-19.00Analyst Report
Incyte logo
INCY
Incyte
1.9$79.63-1.2%$17.29 billion$2.16 billion-50.72
Novavax logo
NVAX
Novavax
1.2$240.29-3.8%$14.72 billion$18.66 million-46.03Gap Down
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.17-2.2%$14.37 billion$1.70 billion18.12Earnings Announcement
Analyst Report
Gap Down
Repligen logo
RGEN
Repligen
1.5$221.73-4.2%$11.63 billion$270.24 million270.40Earnings Announcement
Analyst Revision
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.4$54.05-3.1%$7.61 billion$1.12 billion112.60Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.7$171.27-2.4%$7.43 billion$1.45 billion16.20Earnings Announcement
Analyst Report
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$22.30-2.9%$6.76 billion$967.78 million46.46Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.47-2.6%$6.12 billion$195.99 million290.44Earnings Announcement
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.6$102.20-6.1%$5.12 billion$1.11 billion32.86Gap Down
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$80.08-0.3%$4.85 billion$806.43 million-11.34Earnings Announcement
Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$68.40-0.8%$4.70 billion$36.13 million-102.09Decrease in Short Interest
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$11.79-4.2%$3.07 billion$182.24 million-10.25
Alkermes logo
ALKS
Alkermes
1.2$19.20-0.8%$3.03 billion$1.17 billion-41.74
OPKO Health logo
OPK
OPKO Health
1.9$4.70-4.3%$3.02 billion$901.90 million-26.11
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$156.52-5.3%$2.46 billion$120.28 million-158.10Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$30.86-1.2%$2.29 billion$638.60 million-11.87Earnings Announcement
Decrease in Short Interest
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.98-10.0%$2.12 billion$48.83 million-15.76Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.54-3.1%$1.87 billionN/A-10.62Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.3$8.95-2.2%$1.70 billion$82.27 million-21.83
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.99-4.2%$1.63 billion$102.43 million-19.98Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.59-3.8%$1.54 billion$428.41 million13.90
Codexis logo
CDXS
Codexis
1.1$23.48-5.8%$1.39 billion$68.46 million-67.09Earnings Announcement
Analyst Report
Gap Down
MannKind logo
MNKD
MannKind
1.4$4.01-42.4%$1.33 billion$63.04 million-19.09Analyst Report
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.40-0.3%$1.16 billion$261.02 million5.82News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.1$5.26-1.3%$1.13 billion$150,000.00-7.51Earnings Announcement
Analyst Report
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$28.19-3.9%$1.07 billion$3.57 million-12.64Analyst Report
Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$18.74-0.5%$1.02 billion$227.19 million52.06Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.90-1.7%$980.54 million$35.22 million-6.50Earnings Announcement
Analyst Downgrade
Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$7.60-5.4%$871.31 million$322.07 million-7.24Gap Down
Agenus logo
AGEN
Agenus
1.6$3.96-1.0%$760.60 million$150.05 million-3.63Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.47-7.2%$755.35 million$59.29 million-29.80Upcoming Earnings
Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.68-0.1%$714.61 million$252 million-2.22Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Curis logo
CRIS
Curis
1.1$10.43-5.7%$578.76 million$10 million-12.72Increase in Short Interest
Gap Down
Geron logo
GERN
Geron
1.4$1.86-3.8%$577.48 million$460,000.00-5.31Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$11.48-5.1%$544.61 million$22.27 million-5.63Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23-3.9%$529.03 million$143.01 million-1.19Earnings Announcement
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.61-5.0%$526.78 million$109.33 million-2.65Gap Down
XOMA logo
XOMA
XOMA
1.6$37.10-2.4%$399.00 million$18.37 million-33.42Decrease in Short Interest
Gap Down
Verastem logo
VSTM
Verastem
1.8$2.44-3.7%$398.97 million$17.46 million-1.73Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$3.88-4.1%$363.57 million$36.63 million-4.56Analyst Report
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19
This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.